What Ojemda’s JCA reveals about new era of clinical HTA in Europe
An analysis of GlobalData’s Drug Pricing (POLI) & HTA database shows no HTA outcome for Ojemda in the wake of the JCA review.
Pricing and Market Access
Turning AI skeptics into AI advocates through high-integrity data
US patent infringement investigation targets German drug price control measures
CDA data reveals trends on drug approvals and reimbursements in Canada
Healthcare cost inflation is back in the headlines
Japan’s FY26 price revision expands G1 repricing and drives price reduction
MFN changing the rules of the game for the Nordic countries
The Most Favored Nation Policy: early insights into Europe’s response
